Treatment of non-alcoholic fatty liver disease

Therapeutics and Clinical Risk Management

Volumn 3, Issue 6, 2007, Pages 1153-1163

  Tolman, Keith G ^a   Dalpiaz, Anthony S ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Fatty liver; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BETAINE; DIDANOSINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; PROBIOTIC AGENT; ROSIGLITAZONE; ROSUVASTATIN; SIBUTRAMINE; TAMOXIFEN; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID; ZIDOVUDINE;

ADD ON THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; APOPTOSIS; BARIATRIC SURGERY; BLOATING; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PROTECTION; LIVER TOXICITY; LOW CALORY DIET; MEDITERRANEAN DIET; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SIDE EFFECT; STEATORRHEA; WEIGHT REDUCTION;

EID: 38049096339     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Abdelmalek MF, Angulo P, et al. 2001. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol, 96:2711-17.
2. Abdelmalek MF, Sanderson SO, et al. 2006. Betaine for treatment of nonalcoholic steatohepatitis. AASLD, October, 2006. Final ID:33. Hepatology, 44(Suppl 1):200A.
3. Adams LA, Lymp JF, et al. 2005. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 129:113-21.
4. Adams LA, Zein CO, et al. 2004. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol, 99:2365-8.
5. Aleffi S, Petrai I, et al. 2005. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology, 42:1339-48.
6. Andersen T, Gluud C, et al. 1991. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol, 12:224-9.
7. Angulo P. 2006. NAFLD, obesity, and bariatric surgery. Gastroenterology, 130:1848-52.
8. Angulo P, Keach JC, et al. 1999. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 30:1356-62.
9. Antonopoulos S, Mikros S, et al. 2006. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis, 184:233-4.
10. Arkan MC, Hevener AL, et al. 2005. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med, 11:191-8.
11. Assy N, Kaita K, et al. 2000. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci, 45:1929-34.
12. Bacon BR, Farahvash MJ, et al. 1994. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology, 107:1103-9.
13. Bajaj M, Suraamornkul S, et al. 2004. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab, 89:200-6.
14. Barker KB, Palekar NA, et al. 2006. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol, 101:368-73.
15. Basaranoglu M, Acbay O, et al. 1999. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol, 31:384.
16. Bataller R, Gabele E, et al. 2003. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol, 285:G642-51.
17. Bataller R, Sancho-Bru P, et al. 2005. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal, 7:1346-55.
18. Bataller R, Schwabe RF, et al. 2003. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest, 112:1383-94.
19. Begriche K, Igoudjil A, et al. 2006. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion, 6:1-28.
20. Belfort R, Harrison SA, et al. 2006. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med, 355:2297-307.
21. Bellentani S, Bedogni G, et al. 2004. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol, 16:1087-93.
22. Browning JD, Szczepaniak LS, et al. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 40:1387-95.
23. Bugianesi E, Gentilcore E, et al. 2005. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol, 100:1082-90.
24. Bugianesi E, Leone N, et al. 2002. Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 123:134-40.
25. Cai D, Yuan M, et al. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med, 11:183-90.
26. Caldwell SH, Crespo DM, et al. 2004. Obesity and hepatocellular carcinoma. Gastroenterology, 127:S97-103.
27. Caldwell SH, Hespenheide EE, et al. 2001. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol, 96:519-25.
28. Calle EE, Thun MJ, et al. 1999. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med, 341:1097-105.
29. Chalasani N, Aljadhey H, et al. 2004. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 126:1287-92.
30. Chalasani N, Gorski JC, et al. 2003. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology, 37:544-50.
31. Chalasani N, Teal B, et al. 2005. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol, 100:1317-21.
32. Clark JM, Alkhuraishi AR, et al. 2005. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res, 13:1180-6.
33. Clark JM, Brancati FL, et al. 2002. Nonalcoholic fatty liver disease. Gastroenterology, 122:1649-57.
34. Cusi K, Consoli A, et al. 1996. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 81:4059-67.
35. Dam-Larsen S, Franzmann M, et al. 2004. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut, 53:750-5.
36. de Marco R, Locatelli F, et al. 1999. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care, 22:756-61.
37. DeFronzo RA, Barzilai N, et al. 1991. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab, 73:1294-301.
38. Diehl AM. 2004. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis, 8:619-38, x.
39. Dixon JB, Bhathal PS, et al. 2004. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology, 39:1647-54.
40. Esposito K, Marfella R, et al. 2004. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA, 292:1440-6.
41. Feldstein AE, Canbay A, et al. 2003a. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology, 125:437-43.
42. Feldstein AE, Canbay A, et al. 2003b. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol, 39:978-83.
43. Feldstein AE, Werneburg NW, et al. 2004. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology, 40:185-94.
44. Flegal KM, Carroll MD, et al. 1998. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord, 22:39-47.
45. Galli A, Crabb DW, et al. 2002. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology, 122:1924-40.
46. Harrison SA, Fincke C, et al. 2004. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther, 20:623-8.
47. Harrison SA, Torgerson S, et al. 2003. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol, 98:2485-90.
48. Hasegawa T, Yoneda M, et al. 2001. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther, 15:1667-72.
49. Hernandez R, Teruel T, et al. 2004. Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-alpha induction of p38 and p42/p44 mitogen-activated protein kinases. Diabetologia, 47:1615-24.
50. Horlander J, Kwo P, et al. 2001. Atorvastatin for the treatment of NASH. Gastroenterology, [abstract] 5:A-544 (2767).
51. Huang MA Greenson JK, et al. 2005. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol, 100:1072-81.
52. Hui JM, Kench JG, et al. 2003. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology, 38:420-7.
53. Iwata M, Haruta T, et al. 2001. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator - activated receptor-gamma. Diabetes, 50:1083-92.
54. James PT, Rigby N, et al. 2004. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil, 11:3-8.
55. Jia DM, Tabaru A, et al. 2000. Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol, 15:1183-91.
56. Joseph AE, Saverymuttu SH, et al. 1991. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol, 43:26-31.
57. Kang H, Greenson JK, et al. 2006. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol, 101:2247-53.
58. Kharroubi I, Ladriere L, et al. 2004. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology, 145:5087-96.
59. Kiyici M, Gulten M, et al. 2003. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol, 17:713-18.
60. Klein S, Mittendorfer B, et al. 2006. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology, 130:1564-72.
61. Kleiner DE, Brunt EM, et al. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41:313-21.
62. Laurin J, Lindor KD, et al. 1996. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology, 23:1464-7.
63. Lavine JE. 2000. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr, 136:734-8.
64. Lee Y, Sutedja D, et al. 2006. A randomized controlled double blind study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatology, 44(Suppl 1):654A.
65. Lin HZ, Yang SQ, et al. 2000. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med, 6:998-1003.
66. Lindor KD, Kowdley KV, et al. 2004. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology, 39:770-8.
67. Livingston B. 2000. Epidemiology of childhood obesity in Europe. Eur J Pediatr, 159 Suppl 1:S14-34.
68. Loguercio C, Federico A, et al. 2005. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol, 39:540-3.
69. Marchesini G, Brizi M, et al. 2001. Metformin in non-alcoholic steatohepatitis. Lancet, 358:893-4.
70. Marchesini G, Brizi M, et al. 1999. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med, 107:450-5.
71. Marchesini G, Bugianesi E, et al. 2003. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 37:917-23.
72. Marubbio AT Jr, Buchwald H, et al. 1976. Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass. Am J Clin Pathol, 66:684-91.
73. Mathurin P, Gonzalez F, et al. 2006. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology, 130:1617-24.
74. Mattar SG, Velcu LM, et al. 2005. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg, 242:610-17; discussion 618-20.
75. Matteoni CA, Younossi ZM, et al. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 116:1413-19.
76. McCullough AJ. 2005. The epidemiology and risk factors of NASH. In Farrell GC, George J, Hall P, et al. Eds. Fatty liver disease: NASH and related disorders. Oxford: Blackwell. p 23-37.
77. McCullough AJ. 2006. Thiazolidinediones for nonalcoholic steatohepatitis - promising but not ready for prime time. N Engl J Med, 355:2361-3.
78. Mendler MH, Kanel G, et al. 2005. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int, 25:294-304.
79. Miller ER 3rd, Pastor-Barriuso R, et al. 2005. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med, 142:37-46.
80. Mitchell DG. 1992. Focal manifestations of diffuse liver disease at MR imaging. Radiology, 185:1-11.
81. Musso G, Gambino R, et al. 2003. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology, 37(4):909-16.
82. Neuschwander-Tetri BA, Brunt EM, et al. 2003. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology, 38:1008-17.
83. Neuschwander-Tetri BA, Caldwell SH. 2003. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 37:1202-19.
84. Nieto N, Friedman SL, et al. 2002. Cytochrome P450 2E1 -derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem, 277:9853-64.
85. Nieto N, Greenwel P, et al. 2000. Ethanol and arachidonic acid increase alpha 2(I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2E1. Role of H2O2 and cyclooxygenase-2. J Biol Chem, 275:20136-45.
86. Patel K, Zekry A, et al. 2005. Steatosis and chronic hepatitis C virus infection: mechanisms and significance. Clin Liver Dis, 9:399-410, vi.
87. Perez-Carreras M, Del Hoyo P, et al. 2003. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 38:999-1007.
88. Petersen KF, Dufour S, et al. 2005. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes, 54:603-8.
89. Powell EE, Cooksley WG, et al. 1990. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology, 11:74-80.
90. Prasad A, Quyyumi AA. 2004. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation, 110:1507-12.
91. Promrat K, Lutchman G, et al. 2004. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 39:188-96.
92. Rallidis LS, Drakoulis CK, et al. 2004. Pravastatin in patients with non-alcoholic steatohepatitis: results of a pilot study. Atherosclerosis, 174:193-6.
93. Ratziu V, Charlotte F, et al. 2005. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology, 128:1898-906.
94. Ratziu V, Charlotte F, et al. 2006. A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis: results of the FLIRT pilot trial. Hepatology, 44(4 Suppl 1):201A.
95. Reeves HL, Burt AD, et al. 1996. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol, 25:677-83.
96. Saadeh S, Younossi ZM, et al. 2002. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 123:745-50.
97. Sabuncu T, Nazligul Y, et al. 2003. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol, 12:189-92.
98. Samuel VT, Liu ZX, et al. 2004. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem, 279:32345-53.
99. Sanyal AJ, Mofrad PS, et al. 2004. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol, 2:1107-15.
100. Satapathy SK, Garg S, et al. 2004. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol, 99:1946-52.
101. Saxena NK, Ikeda K, et al. 2002. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology, 35:762-71.
102. Saxena NK, Titus MA, et al. 2004. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. Faseb J, 18:1612-14.
103. Schwimmer JB, Middleton MS, et al. 2005. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 21:871-9.
104. Shadid S, Jensen MD. 2003. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol, 1:384-7.
105. Shulman GI. 2000. Cellular mechanisms of insulin resistance. J Clin Invest, 106:171-6.
106. Siegelman ES, Rosen MA. 2001. Imaging of hepatic steatosis. Semin Liver Dis, 21:71-80.
107. Silverman JF, O'Brien KF, et al. 1990. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol, 85:1349-55.
108. Silverman JF, Pories WJ, et al. 1989. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu, 24 Pt 1: 275-302.
109. Solga S, Alkhuraishe AR, et al. 2004. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci, 49:1578-83.
110. Sorbi D, Boynton J, et al. 1999. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol, 94:1018-22.
111. Struben VM, Hespenheide EE, et al. 2000. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med, 108:9-13.
112. Stumvoll M, Nurjhan N, et al. 1995. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 333:550-4.
113. Suzuki A, Lindor K, et al. 2005. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol, 43:1060-6.
114. Teli MR, James OF, et al. 1995. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology, 22:1714-19.
115. Tiikkainen M, Hakkinen AM, et al. 2004. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes, 53:2169-76.
116. Tolman KG, Chandramouli J. 2003. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis, 7:369-79, vi.
117. Uygun A, Kadayifci A, et al. 2004. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 19:537-44.
118. Vajro P, Franzese A, et al. 2000. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr, 136:739-43.
119. Wanless IR, Lentz JS. 1990. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology, 12:1106-10.
120. Weltman MD, Farrell GC, et al. 1998. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology, 27:128-33.
121. Willner IR, Waters B, et al. 2001. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol, 96:2957-61.
122. Yokohama S, Tokusashi Y, et al. 2006. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol, 12:322-6.
123. Yokohama S, Yoneda M, et al. 2004. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology, 40:1222-5.
124. You M, Crabb DW 2004. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol, 287:G1-6.
125. Zelber-Sagi S, Kessler A, et al. 2006. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 4:639-44.